Paolo Marzullo

List of Publications by Year
in descending order

172	9,216	36203	45213
papers	citations	51 h-index	90 g-index

179	179	179	7361
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews, 2004, 25, 102-152.	8.9	1,093
2	Persistence of Increased Cardiovascular Risk in Patients with Cushingâ€™s Disease after Five Years of Successful Cure. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2664-2672.	1.8	344
3	Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Network Open, 2021, 4, e2036142.	2.8	336
4	Growth hormone and the heart. Clinical Endocrinology, 2001, 54, 137-154.	1.2	328
5	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2779-2786.	1.8	242
6	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2779-2786.	1.8	214
7	Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3308-3314.	1.8	199
8	MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. European Journal of Endocrinology, 2014, 171, R137-R152.	1.9	174
9	Investigations of Thyroid Hormones and Antibodies in Obesity: Leptin Levels Are Associated with Thyroid Autoimmunity Independent of Bioanthropometric, Hormonal, and Weight-Related Determinants. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3965-3972.	1.8	173
10	The Relationship between Active Ghrelin Levels and Human Obesity Involves Alterations in Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 936-939.	1.8	160
11	Vitamin D and Neurological Diseases: An Endocrine View. International Journal of Molecular Sciences, 2017, 18, 2482.	1.8	160
12	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 193-199.	1.8	154
13	Effect of Different Dopaminergic Agents in the Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 518-523.	1.8	140
14	Prediction of efficacy of octreotide therapy in patients with acromegaly.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2356-2362.	1.8	126
15	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 193-199.	1.8	123
16	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3196-3201.	1.8	119
17	Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 17-23.	1.8	115
18	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	1.8	102

#	Article	IF	Citations
19	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology, 2001, 54, 515-524.	1.2	101
20	Early Vascular Alterations in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3174-3179.	1.8	100
21	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4099-4103.	1.8	99
22	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12Âmonths of treatment with the depot long-acting somatostatin analogue octreotide. Clinical Endocrinology, 2003, 58, 169-176.	1.2	99
23	Deep Subcutaneous Adipose Tissue: A Distinct Abdominal Adipose Depot. Obesity, 2007, 15, 1933-1943.	1.5	97
24	Evaluation of a Multisensor Armband in Estimating Energy Expenditure in Obese Individuals. Obesity, 2006, 14, 2217-2223.	1.5	96
25	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Scientific Reports, 2020, 10, 20731.	1.6	96
26	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3132-3140.	1.8	95
27	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 775-779.	1.8	94
28	Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutrition Research Reviews, 2018, 31, 291-301.	2.1	90
29	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clinical Endocrinology, 1997, 47, 23-28.	1.2	89
30	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3001-3008.	1.8	84
31	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4099-4103.	1.8	83
32	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1999, 1, 115-120.	1.6	81
33	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	1.8	81
34	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 2000, 53, 53-60.	1.2	77
35	Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. Journal of Endocrinological Investigation, 2002, 25, 971-976.	1.8	77
36	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3132-3140.	1.8	75

#	Article	IF	Citations
37	Impact of Patientâ€™s Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1518-1523.	1.8	71
38	Acromegalic Axial Arthropathy: A Clinical Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 598-603.	1.8	71
39	The lullaby of the sun: the role of vitamin D in sleep disturbance. Sleep Medicine, 2019, 54, 262-265.	0.8	71
40	Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2121-2125.	1.8	70
41	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	1.8	67
42	Severe impairment of bone mass and turnover in Cushingâ€™s disease: comparison between childhood-onset and adulthood-onset disease. Clinical Endocrinology, 2002, 56, 153-158.	1.2	67
43	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3001-3008.	1.8	67
44	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. Journal of Endocrinological Investigation, 1999, 22, 40-47.	1.8	65
45	The pathophysiology of abdominal adipose tissue depots in health and disease. Hormone Molecular Biology and Clinical Investigation, 2014, 19, 57-74.	0.3	65
46	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clinical Endocrinology, 1999, 51, 611-618.	1.2	64
47	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. European Journal of Endocrinology, 2002, 146, 303-309.	1.9	63
48	Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. Journal of Endocrinological Investigation, 2005, 28, 440-448.	1.8	63
49	Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. Journal of Gastroenterology, 2005, 40, 833-835.	2.3	56
50	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3854-3860.	1.8	56
51	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. European Journal of Endocrinology, 2003, 148, 31-38.	1.9	55
52	Thyroid incidentaloma identified by ¹⁸Fâ€fluorodeoxyglucose positron emission tomography with CT (FDGâ€PET/CT): clinical and pathological relevance. Clinical Endocrinology, 2011, 75, 528-534.	1.2	53
53	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology, 2000, 53, 13-19.	1.2	52
54	Effect of Growth Hormone on Cardiac Function. Hormone Research, 1997, 48, 38-42.	1.8	51

#	Article	IF	Citations
55	NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Hormone and IGF Research, 2007, 17, 288-296.	0.5	51
56	One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine, 2015, 50, 620-626.	1.1	50
57	Hypopituitarism following brain injury: when does it occur and how best to test?. Pituitary, 2012, 15, 20-24.	1.6	46
58	The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. Journal of Endocrinological Investigation, 1999, 22, 176-183.	1.8	42
59	New Medical Approaches in Pituitary Adenomas. Hormone Research in Paediatrics, 2000, 53, 76-87.	0.8	42
60	The Impact of Growth Hormone/Insulin-Like Growth Factor-I Axis and Nocturnal Breathing Disorders on Cardiovascular Features of Adult Patients with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5639-5646.	1.8	42
61	Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clinical Endocrinology, 2006, 65, 492-499.	1.2	42
62	Cardiovascular aspects in acromegaly: Effects of treatment. Metabolism: Clinical and Experimental, 1996, 45, 57-60.	1.5	41
63	Subcutaneous Abdominal Adipose Tissue Subcompartments: Potential Role in Rosiglitazone Effects. Obesity, 2008, 16, 1983-1991.	1.5	41
64	Diagnosis and treatment of GH deficiency in Praderâ€“Willi syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 785-794.	2.2	41
65	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. International Journal of Obesity Supplements, 2020, 10, 35-49.	12.5	40
66	Immunomodulatory Effects of Vitamin D in Thyroid Diseases. Nutrients, 2020, 12, 1444.	1.7	39
67	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3754-3761.	1.8	38
68	Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. Journal of Endocrinological Investigation, 2008, 31, 765-772.	1.8	37
69	Acylated ghrelin decreases during acute exercise in the lean and obese state. Clinical Endocrinology, 2008, 69, 970-971.	1.2	36
70	Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovascular Diabetology, 2014, 13, 57.	2.7	36
71	Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases. Nutrients, 2020, 12, 789.	1.7	36
72	Altered multisensory temporal integration in obesity. Scientific Reports, 2016, 6, 28382.	1.6	35

#	Article	IF	Citations
73	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3754-3761.	1.8	35
74	CV 205-502 treatment in therapy-resistant acromegalic patients. European Journal of Endocrinology, 1995, 132, 559-564.	1.9	32
75	Simultaneous and Bilateral Inferior Petrosal Sinus Sampling for the Diagnosis of Cushing’s Syndrome: Comparison of Multihormonal Assay, Baseline Multiple Sampling and ACTH-Releasing Hormone Test. Hormone Research, 1993, 40, 209-216.	1.8	31
76	Predictors of Postabsorptive Ghrelin Secretion after Intake of Different Macronutrients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4124-4130.	1.8	31
77	Effects of a Chronic Treatment with Octreotide in Patients with Functionless Pituitary Adenomas. Hormone Research, 1993, 40, 149-155.	1.8	29
78	Conditional Cardiovascular Response to Growth Hormone Therapy in Adult Patients with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1364-1371.	1.8	29
79	Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. Journal of Endocrinological Investigation, 2019, 42, 397-402.	1.8	28
80	Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. Biomolecules, 2021, 11, 125.	1.8	27
81	THERAPY OF ENDOCRINE DISEASE: GH therapy in adult GH deficiency: A review of treatment schedules and the evidence for low starting doses. European Journal of Endocrinology, 2013, 168, R55-R66.	1.9	26
82	Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2356-2362.	1.8	25
83	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clinical Endocrinology, 2005, 63, 342-349.	1.2	25
84	Is Caloric Restriction Associated with Better Healthy Aging Outcomes? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2020, 12, 2290.	1.7	25
85	Irisin levels in genetic and essential obesity: clues for a potential dual role. Scientific Reports, 2020, 10, 1020.	1.6	25
86	Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism. Growth Hormone and IGF Research, 2013, 23, 109-113.	0.5	24
87	Obesity modifies expression profiles of metabolic markers in superficial and deep subcutaneous abdominal adipose tissue depots. Endocrine, 2014, 46, 99-106.	1.1	24
88	Insights into non-classic and emerging causes of hypopituitarism. Nature Reviews Endocrinology, 2021, 17, 114-129.	4.3	24
89	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. Disease Markers, 2021, 2021, 1-7.	0.6	24
90	Analysis of Predictive Equations for Estimating Resting Energy Expenditure in a Large Cohort of Morbidly Obese Patients. Frontiers in Endocrinology, 2018, 9, 367.	1.5	23

#	Article	IF	Citations
91	Vitamin D as a Biomarker of Ill Health among the Over-50s: A Systematic Review of Cohort Studies. Nutrients, 2019, 11, 2384.	1.7	23
92	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. , 0, .		23
93	Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Frontiers in Endocrinology, 2020, 11, 591501.	1.5	23
94	Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS). Endocrine, 2016, 52, 441-450.	1.1	22
95	Non-surgical ablative therapies for inoperable benign insulinoma. Journal of Endocrinological Investigation, 2018, 41, 153-162.	1.8	22
96	Plasma Oxytocin Concentration in Pre- and Postmenopausal Women: Its Relationship with Obesity, Body Composition and Metabolic Variables. Obesity Facts, 2018, 11, 429-439.	1.6	22
97	Comparison among Different Dopamine-Agonists of New Formulation in the Clinical Management of Macroprolactinomas. Hormone Research, 1995, 44, 222-228.	1.8	21
98	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clinical Endocrinology, 1999, 51, 159-164.	1.2	21
99	Lymphocyte subset pattern in acromegaly. Journal of Endocrinological Investigation, 2002, 25, 125-128.	1.8	21
100	Leptin Concentrations in GH Deficiency: The Effect of GH Insensitivity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 540-545.	1.8	21
101	Growth hormone deficiency in treated acromegaly. Trends in Endocrinology and Metabolism, 2015, 26, 11-21.	3.1	20
102	The relationship between resting energy expenditure and thyroid hormones in response to short-term weight loss in severe obesity. PLoS ONE, 2018, 13, e0205293.	1.1	20
103	Early Vascular Alterations in Acromegaly. , 0, .		20
104	Sagittal abdominal diameter is more predictive of cardiovascular risk than abdominal fat compartments in severe obesity. International Journal of Obesity, 2009, 33, 233-238.	1.6	19
105	Thyroid cancer phenotypes in relation to inflammation and autoimmunity. Frontiers in Bioscience - Landmark, 2018, 23, 2267-2282.	3.0	19
106	Clinicalâ€“pathological changes in differentiated thyroid cancer (DTC) over time (1997â€“2010): data from the University Hospital â€œMaggiore della CaritÃ â€•in Novara. Endocrine, 2012, 42, 382-390.	1.1	18
107	Lymphocytes and immunoglobulin patterns across the threshold of severe obesity. Endocrine, 2014, 45, 392-400.	1.1	18
108	Acute Vitamin D3 Supplementation in Severe Obesity: Evaluation of Multimeric Adiponectin. Nutrients, 2017, 9, 459.	1.7	18

#	Article	IF	Citations
109	Cardiac Effect of Thyrotoxicosis in Acromegaly¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1426-1432.	1.8	17
110	Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy. Endocrine, 2020, 69, 107-112.	1.1	17
111	Percutaneous ethanol injection under Power Doppler ultrasound assistance in the treatment of autonomously functioning thyroid nodules. Journal of Endocrinological Investigation, 1999, 22, 752-759.	1.8	16
112	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. European Journal of Endocrinology, 2000, 143, 61-69.	1.9	16
113	Body fat excess and stimulated growth hormone levels in adult patients with Praderâ€“Willi syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 726-731.	0.7	16
114	Clinical picture and the treatment of TBI-induced hypopituitarism. Pituitary, 2019, 22, 261-269.	1.6	16
115	Circulating angiopoietin-like 8 (ANGPTL8) is a marker of liver steatosis and is negatively regulated by Prader-Willi Syndrome. Scientific Reports, 2017, 7, 3186.	1.6	15
116	Neuroinflammation and Hypothalamo-Pituitary Dysfunction: Focus of Traumatic Brain Injury. International Journal of Molecular Sciences, 2021, 22, 2686.	1.8	15
117	Cardiac Effect of Thyrotoxicosis in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1426-1432.	1.8	15
118	Muscle Sympathetic Nerve Activity in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3203-3207.	1.8	14
119	Long-term Echocardiographic and Cardioscintigraphic Effects of Growth Hormone Treatment in Adults With Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2106-2114.	1.8	14
120	Exploring extra dimensions to capture saliva metabolite fingerprints from metabolically healthy and unhealthy obese patients by comprehensive two-dimensional gas chromatography featuring Tandem Ionization mass spectrometry. Analytical and Bioanalytical Chemistry, 2021, 413, 403-418.	1.9	14
121	Breast Cancer Diet â€œBCDâ€• A Review of Healthy Dietary Patterns to Prevent Breast Cancer Recurrence and Reduce Mortality. Nutrients, 2022, 14, 476.	1.7	14
122	Abdominal fat index by ultrasound does not estimate the metabolic risk factors of cardiovascular disease better than waist circumference in severe obesity. Diabetes and Metabolism, 2005, 31, 471-477.	1.4	13
123	Deconvolutionâ€based assessment of pituitary <scp>GH</scp> secretion stimulated with <scp>GHRH</scp>+arginine in <scp>P</scp>raderâ€<scp>W</scp>illi adults and obese controls. Clinical Endocrinology, 2013, 79, 224-231.	1.2	13
124	Short bouts of anaerobic exercise increase non-esterified fatty acids release in obesity. European Journal of Nutrition, 2014, 53, 243-249.	1.8	13
125	The impact of the metabolic phenotype on thyroid function in obesity. Diabetology and Metabolic Syndrome, 2016, 8, 59.	1.2	13
126	Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes. Journal of Endocrinological Investigation, 2011, 34, 493-7.	1.8	13

#	Article	IF	Citations
127	Dynamics of GH secretion during incremental exercise in obesity, before and after a short period of training at different work-loads. Clinical Endocrinology, 2010, 73, no-no.	1.2	12
128	Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4527-e4530.	1.8	12
129	Circulating adipokines and metabolic setting in differentiated thyroid cancer. Endocrine Connections, 2019, 8, 997-1006.	0.8	12
130	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. Clinical Endocrinology, 1996, 45, 157-166.	1.2	11
131	Serum uric acid potentially links metabolic health to measures of fuel use in lean and obese individuals. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1029-1035.	1.1	11
132	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. European Journal of Endocrinology, 1995, 133, 189-194.	1.9	10
133	Leptin Level Lowers in Proportion to the Amount of Aerobic Work After Four Weeks of Training in Obesity. Hormone and Metabolic Research, 2015, 47, 225-231.	0.7	10
134	Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma. Endocrine, 2021, 71, 149-157.	1.1	10
135	Spot-light on microbiota in obesity and cancer. International Journal of Obesity, 2021, 45, 2291-2299.	1.6	10
136	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. Journal of Endocrinological Investigation, 2022, 45, 1587-1598.	1.8	10
137	Inherent insulin sensitivity is a major determinant of multimeric adiponectin responsiveness to short-term weight loss in extreme obesity. Scientific Reports, 2015, 4, 5803.	1.6	8
138	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine, 2016, 53, 551-557.	1.1	8
139	Levothyroxine Replacement in Obese Adults: The Role of Metabolic Variables and Aging on Thyroid Testing Abnormalities. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6265-6274.	1.8	8
140	Assessment of fat-free mass from bioelectrical impedance analysis in men and women with Prader-Willi syndrome: cross-sectional study. International Journal of Food Sciences and Nutrition, 2019, 70, 645-649.	1.3	8
141	CV 205â€“502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomedicine and Pharmacotherapy, 1994, 48, 167-174.	2.5	7
142	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. Gynecological Endocrinology, 1995, 9, 15-21.	0.7	7
143	Acromegaly and prostate cancer. Growth Hormone and IGF Research, 2000, 10, S37-S38.	0.5	7
144	Transsphenoidal surgery for pituitary adenomas: early results from a single center. Hormones, 2018, 17, 551-556.	0.9	7

#	Article	IF	Citations
145	Stimulated GH levels during the transition phase in Praderâ€“Willi syndrome. Journal of Endocrinological Investigation, 2021, 44, 1465-1474.	1.8	7
146	Dynamic Tests in Pituitary Endocrinology: Pitfalls in Interpretation during Aging. Neuroendocrinology, 2022, 112, 1-14.	1.2	7
147	Lack of association between the tetranucleotide repeat polymorphism in the 3â€²-flanking region of the leptin gene and hypertension in severly obese patients. Journal of Endocrinological Investigation, 2006, 29, 776-780.	1.8	6
148	Altered temporal sensitivity in obesity is linked to pro-inflammatory state. Scientific Reports, 2019, 9, 15508.	1.6	6
149	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. Journal of Endocrinological Investigation, 2022, 45, 1465-1481.	1.8	6
150	Corticotropin Releasing Hormone Administration Increases Alpha-Melanocyte-Stimulating Hormone Levels in the Inferior Petrosal Sinuses in a Subset of Patients with Cushing’s Disease. Hormone Research, 1996, 46, 26-32.	1.8	5
151	Fat-Free Mass Is Better Related to Serum Uric Acid Than Metabolic Homeostasis in Prader-Willi Syndrome. Nutrients, 2020, 12, 2583.	1.7	5
152	Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome. Journal of Endocrinological Investigation, 2021, 44, 1447-1456.	1.8	5
153	Aging and comorbidities influence the risk of hospitalization and mortality in diabetic patients experiencing severe hypoglycemia. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 160-166.	1.1	5
154	Obesity and Bone Loss at Menopause: The Role of Sclerostin. Diagnostics, 2021, 11, 1914.	1.3	5
155	Gestational Diabetes Mellitus: Clinical Characteristics and Perinatal Outcomes in a Multiethnic Population of North Italy. International Journal of Endocrinology, 2021, 2021, 1-10.	0.6	5
156	Bone Response to Weight Loss Following Bariatric Surgery. Frontiers in Endocrinology, 0, 13, .	1.5	5
157	The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC). European Journal of Clinical Nutrition, 2020, 74, 1038-1046.	1.3	4
158	Playing around the anaerobic threshold during COVID-19 pandemic: advantages and disadvantages of adding bouts of anaerobic work to aerobic activity in physical treatment of individuals with obesity. Acta Diabetologica, 2021, 58, 1329-1341.	1.2	4
159	Thyrotropic Axis and Disorders of Consciousness in Acquired Brain Injury: A Potential Intriguing Association?. Frontiers in Endocrinology, 0, 13, .	1.5	4
160	Prostatic Hyperplasia in Patients with Acromegalyâ€”Authorsâ€™ Response. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2606-a-2607.	1.8	3
161	Acromegaly and immune function. NeuroImmune Biology, 2002, , 247-257.	0.2	3
162	Cocaine Abuse and Sleep Apnea in Severe Obesity. Journal of Addiction Medicine, 2013, 7, 294-295.	1.4	2

#	Article	IF	Citations
163	Diabetes in Growth Hormone Deficiency. Frontiers in Diabetes, 2014, , 10-21.	0.4	2
164	Growth hormone disorders in adults. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 1-2.	2.2	2
165	New Insights on Low Vitamin D Plasma Concentration as a Potential Cardiovascular Risk Factor.. Open Rheumatology Journal, 2018, 12, 261-278.	0.1	2
166	Growth hormone deficiency in children. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 677-678.	2.2	1
167	Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life. Hormones, 2018, 16, 396-404.	0.9	1
168	Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity. Frontiers in Endocrinology, 2021, 12, 687918.	1.5	1
169	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. Journal of Urology, 1998, 160, 1583-1584.	0.2	0
170	Trattamento dellâ€™acromegalia: attualitÃ e prospettive. L Endocrinologo, 2001, 2, 99-109.	0.0	0
171	Low-Intensity Whole-Body Vibration: A Useful Adjuvant in Managing Obesity? A Pilot Study. Applied Sciences (Switzerland), 2021, 11, 5101.	1.3	0
172	Circulating Irisin in Children and Adolescents With Prader-Willi Syndrome: Relation With Glucose Metabolism. Frontiers in Endocrinology, 0, 13, .	1.5	0